Analyst Ratings for Krystal Biotech (KRYS)
KRYS Rating Summary
KRYS Price Target Summary
- Highest: $403.00 (TD Cowen)
- Lowest: $216.00 (Chardan)
- Average: $335.88
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$335.88 (-3.5%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
Avg. $ Target:
$335.88 (-3.5%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/26/2026 | Wolfe Research | Kalpit Patel | New Coverage | Peerperform (N/A) |
N/A (N/A) |
254.95 (348.06) |
36.52% | Details |
| 1/6/2026 | Citi » Updated 1/9/2026 |
Yigal Nochomovitz | Upgrade | Buy (Neutral) |
320.00 (309.00) |
244.71 (348.06) |
42.23% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
